Eli Lilly

Eli Lilly and Company engages in the discovery, development, manufacture, and sale of products in pharmaceutical products business segment. The Сompany also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production. Its prodcuts, include Zyprexa, for the treatment of schizophrenia, acute mixed or manic episodes associated with bipolar I disorder, and bipolar maintenance; Cymbalta, for the treatment of major depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, and in the United States for the management of fibromyalgia; Strattera, for the treatment of attention-deficit hyperactivity disorder in children, adolescents and adults; Prozac, for the treatment of major depressive disorder, obsessive-compulsive disorder, bulimia nervosa and panic disorder; and Symbyax, for the treatment of bipolar depression. Endocrinology products, include: Humalog, Humalog Mix 75/25, and Humalog Mix 50/50tm, for the treatment of diabetes; Humulin, for the treatment of diabetes; Byetta, for the treatment of type 2 diabetes; Actos, for the treatment of type 2 diabetes; Evista, for the prevention and treatment of osteoporosis in postmenopausal women and for the reduction of the risk of invasive breast cancer in postmenopausal women with osteoporosis and postmenopausal women at high risk for invasive breast cancer; Forteo, for the treatment of osteoporosis in postmenopausal women and men at high risk for fracture; and Humatrope, for the treatment of human growth hormone deficiency and idiopathic short stature.

Company Growth (employees)
Type
Public
HQ
Indianapolis, US
Founded
1876
Size (employees)
41,975 (est)
Website
lilly.com
Eli Lilly was founded in 1876 and is headquartered in Indianapolis, US

Key People at Eli Lilly

John Lechleiter

John Lechleiter

Chairman, President, and CEO
David Ricks

David Ricks

President and Chief Executive Officer
Jan Lundberg

Jan Lundberg

Executive Vice President
Alfonso Zulueta

Alfonso Zulueta

Senior Vice President and President
Barton Peterson

Barton Peterson

Senior Vice President, Corporate Affairs and Communications
Derica Rice

Derica Rice

Executive Vice President, Global Services, and Chief Financial Officer
Jeffrey Simmons

Jeffrey Simmons

Senior Vice President
Melissa Barnes

Melissa Barnes

Senior Vice President
Enrique Conterno

Enrique Conterno

Senior Vice President
Maria Crowe

Maria Crowe

President, Manufacturing Operations
Michael Harrington

Michael Harrington

Senior Vice President and General Counsel
Stephen Fry

Stephen Fry

Senior Vice President, Human Resources and Diversity
Susan Mahony

Susan Mahony

Senior Vice President and President
Fionnuala Walsh

Fionnuala Walsh

Senior Vice President

Eli Lilly Office Locations

Eli Lilly has offices in Indianapolis, Chuo Ward, Wien, Melrose Park and in 2 other locations
Indianapolis, US (HQ)
Lilly Corporate Center
Toronto, CA
3650 Danforth Ave
Windlesham, GB
Erl Wood Manor Sunninghill Road
Melrose Park, AU
112 Wharf Rd
Wien, AT
8-10 Kölblgasse
Chuo Ward, JP
Sannomiya Plaza Building 7-1-5 Isogami-dori Chuo-ku, Kobe

Eli Lilly Data and Metrics

Eli Lilly Financial Metrics

Eli Lilly's revenue was reported to be $21.2 b in FY, 2016 which is a 6% increase from the previous period.
USD

Revenue (FY, 2016)

21.2 b

Revenue growth (FY, 2015 - FY, 2016), %

6%

Gross profit (FY, 2016)

15.6 b

Gross profit margin (FY, 2016), %

73%

Net income (FY, 2016)

2.7 b

Market capitalization (22-Sep-2017)

88.7 b

Cash (31-Dec-2016)

4.6 b

EV

92.5 b
Eli Lilly's current market capitalization is $88.7 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

23.1 b19.6 b20 b21.2 b

Revenue growth, %

(15%)2%6%

Cost of goods sold

4.9 b4.9 b5 b5.7 b

Gross profit

18.2 b14.7 b14.9 b15.6 b
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

3.8 b3.9 b3.7 b4.6 b

Accounts Receivable

588.4 m566.7 m558.6 m736.9 m

Inventories

2.9 b2.7 b3.4 b3.6 b

Current Assets

13.1 b12.2 b12.6 b15.1 b
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

4.7 b2.4 b2.4 b2.7 b

Cash From Operating Activities

5.7 b4.4 b2.8 b4.9 b

Purchases of PP&E

(1 b)(1.2 b)(1.1 b)(1 b)

Cash From Investing Activities

(2.1 b)(3.9 b)26.8 m(3.1 b)
USDY, 2016

EV/CFO

19.1 x

Revenue/Employee

511.3 k

Debt/Equity

0.6 x

Debt/Assets

0.2 x

Financial Leverage

2.8 x
Show all financial metrics

Eli Lilly Operating Metrics

FY, 2013FY, 2014FY, 2015FY, 2016

Projects in R&D Pipeline

57576566

Phase III Trials

871719
Show all operating metrics

Eli Lilly Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
CoLucid PharmaceuticalsJanuary 18, 2017$960 m
Novartis Animal HealthApril 22, 2014$5.4 b
Avid RadiopharmaceuticalsNovember 08, 2010$800 m
Alnara PharmaceuticalsJuly 02, 2010$280 m
Imclone SystemsOctober 06, 2008$6.5 b

Eli Lilly Market Value History

Eli Lilly Median Salaries

Source: 117 public H-1B filings from Eli Lilly

Traffic Overview of Eli Lilly

Eli Lilly Online and Social Media Presence

Eli Lilly News and Updates

Pfizer leads Big Pharma's emerging markets growth as GlaxoSmithKline, Eli Lilly lag

Big Pharma expanded in emerging markets 6.1% last quarter, the biggest jump in more than two years, but GlaxoSmithKline and Eli Lilly didn't reap as much growth as their peers—and all of them may face rising threats ahead.

Eli Lilly Company Life and Culture

You may also be interested in